TSHA Stock Analysis: Buy, Sell, or Hold?
TSHA - Taysha Gene Therapies, Inc. Common Stock
$5.46
-0.50 (-8.39%)
▼
5d:
-19.94%
30d:
-15.09%
90d:
+19.21%
WAIT
LOW Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 20, 2026
1d
Smart Money Accumulation
TSHA is down 12.5% this week, but smart money is accumulating calls. Top strike: $9 2026-07-17 with 12,492 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When TSHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TSHA is down 19.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TSHA is down 19.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TSHA is currently trading at $5.46, which is considered slightly low relative to its 30-day fair value range of $5.44 to $6.90.
Technical Outlook: Technically, TSHA is in a uptrend. The price is currently testing key support at $5.61. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.86 (+98.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TSHA is in a uptrend. The price is currently testing key support at $5.61. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.86 (+98.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$5.44 -
$6.90
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.4%)
- BULLISH: Trading 98.9% below Wall St target ($11.86)
- WARNING: Recommendation downgraded due to -19.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$5.44 -
$6.90
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$5.61
Resistance Level
$7.30
Current Trend
Uptrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-13.03
Wall Street Target
$11.86
(+98.9%)
Revenue Growth (YoY)
171.3%
Share & Embed Analysis
Last updated: May 18, 2026 2:41 PM ET
Data refreshes hourly during market hours. Next update: 3:41 PM
Data refreshes hourly during market hours. Next update: 3:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TSHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Sukumar Nagendran
SELL
200000 shares
2026-04-10
Kamran Alam
SELL
1655 shares
2026-02-04
Kamran Alam
SELL
23849 shares
2026-01-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 57 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$126 | 55 HOLD |
